Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Loewe, Sun Jae Y. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000
Reexamination Certificate
active
07906529
ABSTRACT:
Disclosed are compounds and pharmaceutically acceptable salts of Formula Iwherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
REFERENCES:
patent: 5104442 (1992-04-01), Schutze et al.
patent: 6395766 (2002-05-01), Broughton et al.
patent: 6395905 (2002-05-01), Bryant et al.
patent: 6716856 (2004-04-01), Pevarello et al.
patent: 2003/0212121 (2003-11-01), Kruger et al.
patent: 2004/0180889 (2004-09-01), Suto et al.
patent: 2004/0220169 (2004-11-01), Gillard et al.
patent: 2006/0258728 (2006-11-01), Tani et al.
patent: 1 571 146 (2005-09-01), None
patent: WO 99/62899 (1999-12-01), None
patent: WO02/20480 (2002-03-01), None
patent: WO 2006/109846 (2006-10-01), None
Stetter et al., caplus an 1956:122272.
Parke, caplus an 1969:491303.
Kubinyi (3D QSAR in Drug Design: Ligand-Protein interactions and molecular similarity, vol. 2-3, Springer, 1998)p. vii, viii, ix, 243,244.
Database Caplus, Chemical Abstracts Service, XP-002386617, Database Accession No. 1968:486902; Abstract, “3-Methyl-6-Phenyl- and -6-.alpha. -furyl-4, 5, 6, 7-tetrahydroindazol-4-one and Their Derivatives”, Latvijas PSR Zinatnu Akademijas Vestis, Kimijas Serija, vol. 2, 1968, pp. 188-191.
Gerhard, Ute et al., Accelerated Metabolite Identification by “Extraction-NMR”, Journal of Pharmaceutical and Biomedical Analysis, vol. 32 (2003), pp. 531-538.
Fukumoto, Shoji et al., “Novel, Non-Acylguanidine-Type Na+/H+ Exchanger Inhibitors: Synthesis and Pharmacology of 5-Tetrahydroquinolinylidene Aminoguanidine Derivatives”, J. Med. Chem., vol. 45 (2002), pp. 3009-3021.
Croce, Piero Dalla et al., “A Convenient Synthesis of Indazoles”, Synthesis, (Nov. 1984), pp. 982-983.
Kim, Jin II et al., “A Versatile Synthesis of Substituted Indazoles”, Heterocycles, vol. 41, No. 7 (1995), pp. 1471-1478.
International Search Report for PCT/US2006/006988, Jul. 10, 2006.
Maloney, Alison et al., “HSP90 as a New Therapeutic Target for Cancer Therapy: The Story Unfolds”, Expert Opinion on Biological Therapy, vol. 2, No. 1 (Jan. 2002), pp. 3-24.
Dymock, Brian W. et al., “Inhibitors of HSP90 and Other Chaperones for the Treatment of Cancer”, Expert Opinion on Therapeutic Patents, vol. 14, No. 6, 2004, pp. 837-847.
Strakova, I. et al., “1-(2-Quinoxalyl)-,1-[3,5-DI-(Trifluoromethyl)Phenyl]-, 1-(2-Carboxyphenyl)-, and 1-Ethoxycarbonyl-4-Oxo-4,5,6,7-Tetrahydroindazoles”, Chemistry of Heterocyclic Compounds, vol. 38, No. 4, 2002, pp. 429-433.
Barta Thomas
Eaves Jeron
Geng Lifeng
Hanson Gunnar
Hinkley Lindsay
Hua Ye
Loewe Sun Jae Y.
Serenex, Inc.
Tidwell Jeffrey H.
LandOfFree
Benzene, pyridine, and pyridazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzene, pyridine, and pyridazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzene, pyridine, and pyridazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778350